Kraig Biocraft Laboratories Announces Second Production Facility, Three Advanced Spider Silk Strains, and New Diapausing System
Kraig Biocraft Laboratories (OTCQB: KBLB) announced three major developments in its spider silk production capabilities. The company is adding a second parallel production facility in Southeast Asia, introducing three new advanced spider silk strains, and implementing a new diapausing system for production.
The new facility, expected to begin parental strain rearing within 30 days, will work in tandem with the existing facility to enable continuous production. The three new spider silk strains were designed to complement the existing BAM-1 hybrid, with two strains specifically bred for controlled diapause - a 90-day cold treatment process for premium silk production.
The company has completed its latest batch of BAM-1 finished spider silk, reaching approximately one-third of the total requirement for a globally renowned European fashion house. These developments aim to significantly increase production yields and spun silk quality while establishing a more resilient supply chain.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha annunciato tre importanti sviluppi nelle sue capacità di produzione di seta di ragno. L'azienda sta aggiungendo un secondo impianto di produzione parallelo nel Sud-est asiatico, introducendo tre nuove varietà avanzate di seta di ragno e implementando un nuovo sistema di diapausa per la produzione.
Il nuovo impianto, che dovrebbe iniziare l'allevamento delle linee parentali entro 30 giorni, lavorerà in sinergia con quello esistente per consentire una produzione continua. Le tre nuove varietà di seta di ragno sono state progettate per integrare l'attuale ibrido BAM-1, con due ceppi specificamente selezionati per la diapausa controllata - un processo di trattamento a freddo di 90 giorni per una produzione di seta di alta qualità.
L'azienda ha completato il suo ultimo lotto di seta di ragno BAM-1 finita, raggiungendo circa un terzo del fabbisogno totale per una casa di moda europea di fama mondiale. Questi sviluppi mirano a incrementare significativamente la resa produttiva e la qualità della seta filata, stabilendo al contempo una catena di approvvigionamento più resiliente.
Kraig Biocraft Laboratories (OTCQB: KBLB) anunció tres avances importantes en sus capacidades de producción de seda de araña. La empresa está añadiendo una segunda instalación de producción paralela en el sudeste asiático, introduciendo tres nuevas cepas avanzadas de seda de araña y implementando un nuevo sistema de diapausa para la producción.
La nueva instalación, que se espera comience la cría de cepas parentales en 30 días, trabajará en conjunto con la instalación existente para permitir una producción continua. Las tres nuevas cepas de seda de araña fueron diseñadas para complementar el híbrido BAM-1 existente, con dos cepas específicamente criadas para diapausa controlada, un proceso de tratamiento en frío de 90 días para la producción de seda premium.
La compañía ha completado su último lote de seda de araña BAM-1 terminada, alcanzando aproximadamente un tercio del requerimiento total para una casa de moda europea de renombre mundial. Estos avances buscan aumentar significativamente los rendimientos de producción y la calidad de la seda hilada, al mismo tiempo que establecen una cadena de suministro más resistente.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 거미줄 생산 능력에서 세 가지 주요 발전 사항을 발표했습니다. 회사는 동남아시아에 두 번째 병행 생산 시설을 추가하고, 세 가지 새로운 고급 거미줄 균주를 도입하며, 생산을 위한 새로운 휴면 시스템을 도입하고 있습니다.
새 시설은 30일 이내에 부모 균주 사육을 시작할 예정이며, 기존 시설과 함께 연속적인 생산을 가능하게 할 것입니다. 세 가지 새로운 거미줄 균주는 기존 BAM-1 하이브리드를 보완하도록 설계되었으며, 그중 두 균주는 고급 실크 생산을 위한 90일 냉처리 과정인 제어된 휴면 상태(디아파우즈)를 위해 특별히 육종되었습니다.
회사는 최근 BAM-1 완제품 거미줄 배치를 완료했으며, 이는 세계적으로 유명한 유럽 패션 하우스를 위한 총 요구량의 약 3분의 1에 해당합니다. 이러한 발전은 생산 수율과 방적 실크 품질을 크게 향상시키고, 더 견고한 공급망을 구축하는 것을 목표로 합니다.
Kraig Biocraft Laboratories (OTCQB : KBLB) a annoncé trois avancées majeures dans ses capacités de production de soie d'araignée. L'entreprise ajoute une deuxième installation de production parallèle en Asie du Sud-Est, introduit trois nouvelles souches avancées de soie d'araignée et met en place un nouveau système de diapause pour la production.
La nouvelle installation, qui devrait commencer l'élevage des souches parentales dans les 30 jours, fonctionnera en tandem avec l'installation existante pour permettre une production continue. Les trois nouvelles souches de soie d'araignée ont été conçues pour compléter l'hybride BAM-1 existant, avec deux souches spécifiquement élevées pour une diapause contrôlée – un processus de traitement à froid de 90 jours pour la production de soie premium.
L'entreprise a terminé son dernier lot de soie d'araignée BAM-1 fini, atteignant environ un tiers des besoins totaux pour une maison de mode européenne de renommée mondiale. Ces développements visent à augmenter significativement les rendements de production et la qualité de la soie filée tout en établissant une chaîne d'approvisionnement plus résiliente.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat drei bedeutende Entwicklungen in seiner Spinnenseidenproduktion bekannt gegeben. Das Unternehmen richtet eine zweite parallele Produktionsanlage in Südostasien ein, führt drei neue fortschrittliche Spinnenseidenstämme ein und implementiert ein neues Diapause-System für die Produktion.
Die neue Anlage, die voraussichtlich innerhalb von 30 Tagen mit der Aufzucht der Elterntiere beginnt, wird parallel zur bestehenden Anlage arbeiten, um eine kontinuierliche Produktion zu ermöglichen. Die drei neuen Spinnenseidenstämme wurden entwickelt, um den bestehenden BAM-1-Hybrid zu ergänzen, wobei zwei Stämme speziell für eine kontrollierte Diapause gezüchtet wurden – ein 90-tägiger Kälteeinlagerungsprozess für die Herstellung von Premiumseide.
Das Unternehmen hat seine jüngste Charge fertiger BAM-1-Spinnenseide abgeschlossen und damit etwa ein Drittel des Gesamtbedarfs für ein weltweit renommiertes europäisches Modehaus erreicht. Diese Entwicklungen zielen darauf ab, die Produktionsausbeute und die Qualität der gesponnenen Seide deutlich zu steigern und gleichzeitig eine widerstandsfähigere Lieferkette aufzubauen.
- None.
- 90-day production transition period required for new diapausing process
- Temporary shift away from finished silk production during transition
- Second facility lease still being finalized
New Architecture lays foundation for Higher Output, continuous Batch Production, and prepares Company for Spider Silk delivery to European based Global Luxury Market Leader
ANN ARBOR, Mich., July 14, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig”, or "Kraig Labs"), a world leader in spider silk technology*, announces the addition of a second parallel production facility, three new advanced spider silk strains, and the immediate launch of a new diapausing system for production. This marks three critical advancements in the Company's high-performance spider silk manufacturing and commercialization to significantly increase production yields and spun silk quality.
Jon Rice, COO of Kraig Labs, recently traveled to the Company’s production facilities in Southeast Asia to organize the launch of this next exciting phase of Kraig's production plan for 2025 and 2026, including a second parallel production facility, three new spider silk strains, and a shift to controlled diapause for production.
A central part of these advancements is the adoption of a second parallel rearing center. A lease for the second facility is being finalized, and parental strain rearing is expected to begin there within the next 30 days.
Kraig Labs completed the development of three new spider silk strains, which are now in the field. These strains, developed over the last year, were designed to complement the Company’s existing BAM-1 hybrid by improving hybrid vigor and increasing silk yield. One of these strains was designed as a replacement for an existing BAM-1 parent lines. Two of these strains were bred to produce silkworms suitable for controlled diapause.
Diapause refers to the silkworm's natural wintering period, a process which can be replicated with a 90-day cold treatment of the silkworm eggs. Diapausing silkworm strains are the gold standard for producing premium silk. One of the Company’s key initial target customers is a widely-renowned producer of the world's finest fabrics and garments, crafted from the highest-quality fibers. Kraig Labs is committed to meeting those standards with its spider silk and the shift to diapausing egg production, along with the addition of a second facility, are key drivers in achieving that goal and increasing production.
Thus far, the Company's production center has operated under a batch production model, bypassing diapause and limiting production to 8 or 9 batches per year. The shift to parallel facilities and the diapausing of eggs (artificial wintering utilizing cold storage treatment) will enable nearly continuous production. These two facilities will operate in tandem to feed that production. While egg production from one facility enters cold storage, the second facility will prepare the next rearing cycle, ensuring a continuous flow of eggs to supply production operations. This new collaborative production system will dramatically expand production capacity far beyond what any single facility could produce independently.
As Kraig Labs rolls out these significant improvements to its operations, the Company is undertaking a production transition period, which includes a 90-day cold treatment cycle for the new diapausing hybrid eggs. This wintering process is widely recognized for yielding stronger, finer silk and significantly larger cocoons than non-diapausing silk. Over the next several months, operational emphasis will shift away from finished silk production and focus on expanding parent line populations and generating the next round of hybrid eggs that Kraig Labs plans to begin releasing in the fourth quarter.
"Deploying two separate rearing centers for our parent lines is a key part of our strategy to build a reliable and scalable supply chain that can address the demand for spider silk and support year-round production," said Kim Thompson, Founder and CEO of Kraig Labs. "This plan, which is the brainchild of our chief sericulture expert, Dr. Kumar, will provide the throughput necessary to support large-scale commercial production and a buffer against potential disruption."
In parallel with these advancements in production operations, Kraig Labs is pleased to announce it has completed the latest batch of BAM-1 finished spider silk. With this newest batch of finished silk complete, the Company has now accumulated approximately one-third of the total spider silk required to fulfill a material request from a globally renowned European fashion house.
"This latest batch brings us another step closer to delivering premium spider silk materials to one of the most recognized names in fashion. The shift to a diapausing hybrid system reflects our long-term vision to deliver the highest quality spider silk at commercial scale," said Rice. "By making this investment in time, infrastructure, and production strategy, we are positioning ourselves to meet the demand we see forming."
Today's announcement marks a significant milestone in Kraig’s commercialization roadmap, accelerating the Company's goal of establishing the world's first cost-effective, environmentally responsible spider silk production platform. The transition to diapausing hybrid rearing and parallel rearing operations enhances supply chain resilience and long-term throughput, as Kraig Labs responds to growing interest from industry.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What are the three major developments announced by Kraig Biocraft (KBLB) in July 2025?
How will the new diapausing system affect KBLB's silk production quality?
What is the status of KBLB's European fashion house order?
How will KBLB's second production facility improve operations?
What are the benefits of KBLB's new spider silk strains?
